Pear Therapeutics, Inc. PEAR
We take great care to ensure that the data presented and summarized in this overview for Pear Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PEAR
Top Purchases
Top Sells
About PEAR
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Insider Transactions at PEAR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2023
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,544,113
-98.02%
|
$0
$0.12 P/Share
|
|
Feb 15
2023
|
Alison Bauerlein Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,428
+50.0%
|
-
|
|
Feb 15
2023
|
Paul Mango Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Shivakumar Rajaraman Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Kirthiga Reddy Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,904
+50.0%
|
-
|
|
Feb 15
2023
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+50.0%
|
-
|
|
Feb 15
2023
|
Timothy A Wicks Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Jan 20
2023
|
Corey Mc Cann President and CEO |
SELL
Open market or private sale
|
Direct |
34,731
-0.42%
|
$34,731
$1.13 P/Share
|
|
Jan 20
2023
|
Yuri Maricich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,162
-11.42%
|
$12,162
$1.13 P/Share
|
|
Jan 20
2023
|
Katherine Jeffery Chief People Officer |
SELL
Open market or private sale
|
Direct |
7,096
-46.08%
|
$7,096
$1.13 P/Share
|
|
Jan 20
2023
|
Christopherd T Guiffre CFO, COO, Treas., & Asst. Sec. |
SELL
Open market or private sale
|
Direct |
19,540
-39.47%
|
$19,540
$1.13 P/Share
|
|
Jan 20
2023
|
Erin K. Brenner Chief Product Dev. Officer |
SELL
Open market or private sale
|
Direct |
8,690
-16.71%
|
$8,690
$1.13 P/Share
|
|
Jan 20
2023
|
Julia Strandberg Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,688
-30.72%
|
$12,688
$1.13 P/Share
|
|
Jan 20
2023
|
Ellen Snow VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
8,027
-25.61%
|
$8,027
$1.13 P/Share
|
|
Jan 20
2023
|
Ronan O'Brien CCO, GC, & Secretary |
SELL
Open market or private sale
|
Direct |
12,162
-39.49%
|
$12,162
$1.13 P/Share
|
|
Jan 14
2023
|
Erin K. Brenner Chief Product Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+29.73%
|
-
|
|
Jan 14
2023
|
Yuri Maricich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+22.43%
|
-
|
|
Jan 14
2023
|
Katherine Jeffery Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+50.0%
|
-
|
|
Jan 14
2023
|
Ronan O'Brien CCO, GC, & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+50.0%
|
-
|
|
Jan 14
2023
|
Julia Strandberg Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+44.41%
|
-
|